NYR-BI03 Phase Ia Clinical Trial Update 2
Highlights: •Nyrada’s Phase Ia Clinical Trial regulatory package has been submitted to Human Research Ethics Committee (HREC). •HREC review expected… Read more
Nyrada Receives A$1.235M R&D Tax Incentive Rebate
Nyrada Inc (ASX:NYR), a drug discovery and development company focused on innovative Transient Receptor Potential Canonical (TRPC) ion channel blockers… Read more
Nyrada -NYR-BI03 Phase Ia Clinical Trial Update – Correction
Highlights: •Nyrada is scheduled to submit its regulatory package to Human Research Ethics Committee (HREC) for review before the end… Read more
Nyrada Investor presentation
Investor Presentation November 2024 Improving Lives, Offering Hope
Nyrada AGM Presentation -James Bonnar CEO
Summary ›Pioneering transient receptor potential canonical (TRPC) channel blocking therapies. ›First-in-class neuroprotection and cardioprotection therapy with novel mode of action…. Read more
Nyrada AGM 2024 Chair’s Address
Good morning, ladies and gentlemen. My name is Dr Gisela Mautner. I am one of the non-executive directors of Nyrada… Read more
Nyrada Successfully Raises $3.36 Million via Placement
Highlights: •Nyrada has successfully raised $3.36 million of new equity capital (before costs) by way of a Placement to institutional,… Read more
Nyrada Inc Investor Presentation
Nyrada Inc Investor Presentation
Nyrada Quarterly Activities Report & Appendix 4C
Highlights: •Nyrada successfully completes Good Laboratory Practice safety studies of lead drug candidate NYR-BI03. •Preclinical efficacy study showed NYR-BI03 provided… Read more